UCLA Researchers Develop Promising Vaccine Against Melioidosis
UCLA researchers have developed a vaccine candidate against Burkholderia pseudomallei, the cause of melioidosis, demonstrating strong protection in mice. The vaccine, delivered intranasally, outperformed skin injection. Melioidosis is a deadly disease with 165,000 cases and 89,000 fatalities annually. The study aims to advance vaccine testing for human safety and efficacy.
UCLA researchers have made significant strides in the fight against melioidosis by developing a new vaccine candidate that has demonstrated strong protective effects in mouse studies. Melioidosis, which is caused by the bacterium Burkholderia pseudomallei, poses a serious health threat, especially in tropical regions. It is estimated that there are 165,000 cases and 89,000 fatalities globally each year. The research, published on November 10, 2026, indicates that a single intranasal dose of the vaccine offers long-lasting immunity against a highly lethal strain of the bacterium, surpassing traditional skin injection methods. This advancement is important for public health, as the disease can lead to rapidly fatal pneumonia and is difficult to diagnose and treat effectively.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Daniel writes about people solving big problems in small, human ways.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
